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Abstract
CD8+ cytotoxic T lymphocytes recognize infected cells in which MHC class I molecules present
pathogen-derived peptides that have been processed mainly by proteasomes. Many infections
induce a set of proteases, the caspases involved in apoptosis or inflammation. In this study, we
report that processing and presentation of a short vaccinia virus-encoded Ag can take place also by
a nonproteasomal pathway, which was blocked in infected cells with chemical inhibitors of
caspases. By cleaving at noncanonical sites, at least two caspases generated antigenic peptides
recognized by T lymphocytes. The sites and the peptidic products were partially overlapping but
different to those used and produced by proteasomes in vitro. Antigenic natural peptides produced
in infected cells by either pathway were quantitatively and qualitatively similar. Finally,
coexpression of the natural vaccinia virus protein B13, which is an inhibitor of caspases and
apoptosis, impaired Ag presentation by the caspase pathway in infected cells. These data support
the hypothesis that numerous cellular proteolytic systems, including those induced during
infection, such as caspases involved in apoptosis or in inflammation, contribute to the repertoire of
presented peptides, thereby facilitating immunosurveillance.
The initial event for Ag presentation of pathogen-derived epitopes is the proteolytic
processing of newly synthesized pathogen proteins. The proteasome is the primary and
major proteolytic complex involved in the cytosolic generation of peptides (1). This
multicatalytic endoprotease is not dedicated to Ag processing and produces a broad diversity
of peptides. Among them, a small fraction of the correct epitope or NH2-terminally extended
precursors can be used for MHC class I Ag presentation. These epitope precursor peptides
may be N-terminally trimmed by aminopeptidases in the cytosol (2). The peptides are then
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transported by TAP to the endoplasmic reticulum lumen and usually require further
trimming to attain the final size epitope. This is performed mainly by endoplasmic reticulum
aminopeptidases (3). Finally, binding to nascent MHC class I molecules generates the
antigenic complex recognized by antiviral CD8+ CTLs at the infected cell surface.
In addition to proteasome-independent and TAP-independent Ag-processing secretory
pathways (4), tripeptidyl peptidase II is the only endoproteolytic activity that can generate
pathogen-derived peptides in the cytosol when proteasomes are inhibited (5, 6). The
potential role of other cytosolic endoproteases in the processing of MHC class I viral ligands
remains to be elucidated. Although it is not expected that these proteases are dedicated to Ag
processing, their peptidic products could be useful for Ag presentation to CD8+ T
lymphocytes. These proteases could thus expand the number of tissues and physiological
and pathological situations compatible with Ag presentation, as well as the range of
pathogen-derived sequences available for recognition by CD8+ T lymphocytes.
Infection by pathogens and the subsequent variety of immune responses may affect the
cellular proteolytic machinery in contrasting ways. Induction of apoptosis after infection by
many pathogens is a widespread phenomenon (7, 8), which always induces activation of a
set of endoproteases, the caspases. Caspases are a family of cytoplasmic cysteine proteases,
some of which are essential for programmed cell death in a variety of species, whereas
others are involved in inflammatory responses (9). They can be detected in many different
types of cells undergoing apoptosis, regardless of their origin or the death stimulus. Initiator
caspases are the first to be activated, followed by effector caspases, which act on cellular
target molecules. In recent years, over 14 different caspases have been identified in
mammals (9). They are synthesized as zymogens with no or very low intrinsic enzymatic
activity. Direct aggregation of initiator caspases after the triggering stimulus is sufficient to
promote self-processing to generate active heterotetramers. Downstream caspases are then
activated proteolytically in a cascade fashion.
In a previous study (10), we investigated Ag processing in cells infected with recombinant
vaccinia viruses (rVACVs) encoding two closely related miniproteins, encompassing murine
CMV pp89 immunodominant epitope (11). In that study, we defined the redundant role of
proteasomes in endogenous Ag processing of short Ags. In the current study, we have
characterized an additional proteasome-independent pathway for Ag processing of one of
these miniproteins, which operates when apoptosis is induced by vaccinia virus infection,
and demonstrate that caspases can generate viral antigenic peptides recognized by CTLs.
Materials and Methods
Mice
BALB/c mice (H-2d haplotype) were bred in our colony in accordance with national
regulations. Animal studies were approved by the review board of Instituto de Salud Carlos
III (Madrid, Spain).
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Lactacystin (LC) was purchased from Dr. E. J. Corey (Harvard University, Boston, MA).
Benzyloxycarbonyl-VAD-fluoromethyl ketone (z-VAD-fmk) and z-FA-fmk inhibitors were
from Bachem (Weil am Rhein, Germany). All three were used at 50 μM both for in vitro
digestions and for cell-based experiments. Ac-WEHD-CHO, Ac-YVAD-CHO, and Ac-
DEVD-CHO caspase inhibitors used in control digestions were purchased from Peptide
Institute (Osaka, Japan). 9pp89 (YPHFMPTNL), m19 (MDIGAYPHFMPTNLAGDPY),
and G9I (GPGRAFVTI) peptides were synthesized in an Applera (Applied Biosystems,
Foster City, CA) peptide synthesizer model 433A, purified, and confirmed to be
homogeneous by HPLC analysis.
Cell lines
Transfected L/Ld and L/Dd cells were obtained from Dr. U. H. Koszinowski (Max-von-
Pettenkofer Institute, München, Germany) (11). The classical IL-2–dependent murine T cell
line CTL-L2 was also used. All cell lines were cultured in IMDM supplemented with 10%
FBS and 5 × 10−5 M 2-ME.
rVACVs
The rVACVs encoding the minigenes rVACV-m17 and rVACV-m19 have been described
previously (12). The rVACV-m17 codes for a 17-mer peptide representing the
immunodominant murine CMV 9pp89 epitope and the local flanking amino acids of
hepatitis B virus e Ag (HBe) carrier protein (MDIGYPHFMPTNLGDPY). The rVACV-
m19 codes for a 19-mer peptide (MDIGAYPHFMPTNLAGDPY) that differs only from the
previous minigene by a biterminal alanine spacer between 9pp89 core and HBe flanking
residues. The recombinant rVACV-HBe was used as a negative control (13). To generate
specific CTL lines in vivo, the murine CMV 9pp89 immunodominant epitope flanked
biterminally by alanines, inserted at the N terminus of HBe, and encoded by rVACV-
HBe/N/A59pp89A5 was used (14). rVACV-sA encodes a secreted, glycosylated 86-aa
protein (15) containing the Ld-restricted murine hepatitis virus nucleocapsid pN epitope
linked to the HIV IIIB gp160 V3 loop comprising the p18 epitope presented by Dd. rVACV-
sI encodes a recombinant 22-aa secretory miniprotein comprising both epitopes. Both
rVACV-sA and rVACV-sI are similar to the published A and I recombinants (16), except
that they are preceded by the adenovirus E19 signal sequence. The vaccinia virus strain
Western Reserve (WR) mutant lacking the B13R gene, vΔB13R, and its revertant control,
vB13R+rev, were reported previously (17) (Fig. 1). The recombinant viruses rVACV-m19,
rVACV-HBe, and rVACV-HBe/N/A59pp89A5 are based on vaccinia virus strain
Copenhagen, which naturally lacks the B13R gene. rVACV-sA, rVACV-sI, vΔB13R, and
vB13R+rev were derived from vaccinia virus strain WR.
T cell lines and cytotoxicity assays
Polyclonal 9pp89-monospecific CTLs were generated by immunization of mice with
rVACV-HBe/N/A59pp89A5 as described previously (11).
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Polyclonal ENV p18-specific CTLs were generated similarly (15). Either 9pp89- or ENV
p18-specific CTLs were used as effector cells in standard 4–6-h cytotoxicity assays (11).
Transfected cells were used as target cells after overnight infection with rVACVs as
described (11). The data are expressed as mean values of at least two experiments.
Recombinant human IL-2 was used for the long-term propagation of CTL lines and was
provided by Hoffmann-La Roche (Basel, Switzerland). The percentage of specific inhibition
was calculated as 100 × (A − Ai)/(A − N), where A is the percent specific lysis with target
cells infected with rVACV-m19, Ai is the value with rVACV-m19 plus inhibitor, and N is
the value with the negative control.
Proteasome and caspase digestion assays
Caspases that were selectively expressed in bacteria and 20S proteasomes were purified as
described (18, 19). m19 digestions by caspases and proteasome were performed as follows
(18, 19): the m19 peptide, dissolved in DMSO, was incubated overnight at room
temperature with micromolar concentrations of different proteases (the proteasome and 10
human caspases) in 0.2 ml. Digestion time was chosen to mimic time of exposure of m19 to
proteases in infected cells. The final concentration of m19 was 0.5 mM, and the incubation
buffer consisted of 0.1 M HEPES (pH 7.5), 10% sucrose, 0.1% CHAPS, and 10 mM DTT.
Postincubation, the samples were frozen at −70°C until further analysis. Similar experiments
in presence of 0.2 mM WEHD-CHO or 2 mM YVAD-CHO (to inhibit caspase-5) or 0.2
mM DEVD-CHO (to block caspase-10 activity) were used as caspase-specificity controls.
Mass spectrometry
Aliquots of total digestions containing peptides were dried and dissolved in 10 μl 0.5%
acetic acid in water and sequenced by quadrupole ion trap micro-HPLC electrospray mass
spectrometry (MS)/MS in a Deca XP LCQ mass spectrometer (Thermo Electron, San Jose,
CA). We used the MS/MS mode and concentrated the analysis on each theoretical parental
peptide (20), using an isolation width (m/z) of 1.5 Da. The charge and mass of the ionic
species were determined by high-resolution sampling of the mass/charge rank. Collision
energy and ion-precursor resolution were improved to optimize the fragmentation spectrum.
All peptides were sequenced by MS/MS fragmentation.
Isolation of naturally processed peptides
L/Ld cells (3 × 108) were infected with rVACV with 10 PFU/cell, and 16 h later, the
naturally processed peptides were extracted from whole cells with trifluoroacetic acid,
purified (21, 22) by reversed phase (RP)-HPLC, and tested in cytotoxicity assays (10) with
9pp89-specific CTLs. As an internal standard, a 9pp89-unrelated peptide was included in all
HPLC runs. To ensure comparability of different runs, the actual conductivity gradient was
monitored. Contamination of the HPLC columns was excluded by testing preceding HPLC
runs with CTLs. For standardization, serial dilutions of synthetic peptides were always
tested in parallel.
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Cells (4 × 105) were infected and/or treated with inhibitors or staurosporine (Sigma-Aldrich,
St. Louis, MO). Four hours later, they were washed and stained with CaspACE FITC-VAD-
fmk in situ marker (Promega, Madison, WI), followed by flow cytometry in a FACScan (BD
Biosciences, Franklin Lakes, NJ).
Results
Caspases inhibitor specifically blocks m19 Ag presentation
The 19-aa–long m19 miniprotein (MDIGAYPHFMPTNLAGDPY) encompasses the
murine CMV pp89 immunodominant and protective nonamer epitope that is presented by
the MHC class I H-2Ld molecule in BALB/c mice (11) and requires proteolytic processing
for TAP-dependent presentation to CD8+ T lymphocytes (10). To study processing of this
miniprotein, the effects of protease inhibitors were investigated. First, processing and
presentation of m19 by H-2Ld-positive target cells following infection with rVACV-m19
(Fig. 1) was confirmed by their lysis by CTL lines specific for the core nonameric epitope
9pp89 (45% specific lysis versus 5% with control rVACV at an E:T ratio of 5:1). Some
reagents, such as LC or z-VAD-fmk, had no effect on the specific recognition by CTLs of
target cells infected with rVACV-m19 (Fig. 2A). LC is a powerful proteasome-specific
inhibitor (23) whose inhibitory effect on Ag presentation was revealed with the m19-related,
2-aa–shorter m17 protein (Fig. 2B) (10). z-VAD-fmk blocks the activity of most caspases
(24). In contrast to the lack of effect of each inhibitor on m19, the combination of both
reagents blocked the presentation of rVACV-m19 completely (Fig. 2A). Because some
nonspecific effects have been ascribed to the fluoro-methyl-ketone moiety of z-VAD-fmk,
we also included the peptide z-FA-fmk as a control. This control compound inhibits
lysosomal cathepsins B and L, but has little effect on caspase activity; only some effector
caspases are inhibited marginally and 10–100-fold less effectively by z-FA-fmk than by z-
VAD-fmk (25). In our studies, m19 Ag presentation was unaffected by this reagent,
regardless of whether it was tested alone or in combination with LC (Fig. 2A). To exclude
the possibility that the inhibitory effects of LC plus z-VAD-fmk were due to toxic effects on
target cells or on rVACV replication, rather than to a specific block of the respective
proteases, similar experiments were performed in parallel using either rVACV-sA or
rVACV-sI viruses, which express secretory proteins that are presented in the presence of LC
following uncharacterized Ag-processing pathways (15). Target cells infected with these
rVACVs and incubated with the mix of LC and z-VAD-fmk were recognized efficiently by
specific CTLs, and no inhibition was detected of either rVACV-sA or rVACV-sI (Fig. 2C,
2D). This excluded any general nonspecific effect on endogenous Ag presentation. These
data thus suggest that inhibition of m19 miniprotein presentation by addition of LC plus z-
VAD-fmk is due to specific blockage of the respective proteases and suggest that the 19-mer
product can be processed in parallel and independently either by proteasomes or by
caspases.
Specific cleavage of m19 synthetic peptide by both caspase-5 and caspase-10
In recent years, the aspartate-specific cysteinyl proteases known as caspases have been
studied intensively both in inflammation and apoptosis (9). Caspases cleave after selected
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Asp residues in selected target proteins. Over 14 caspases have been identified, and 10 of the
human enzymes have been selectively expressed in bacteria, purified, and characterized
thoroughly (18). A similar set of purified murine caspases is not available. Purified human
caspase-1 through caspase-10 were incubated with m19 synthetic peptide, exactly the same
substrate as expressed in living rVACV-m19–infected cells. The potential peptides
generated after enzymatic digestion were separated by RP-HPLC and analyzed in
cytotoxicity assays with 9pp89-specific CTLs (Fig. 3). In all cases, an antigenic activity that
coelutes with the unprocessed m19 substrate peptide was observed. This 19-aa–long
synthetic peptide is recognized by CTLs specific for the 9pp89 nonamer, but it is 103 times
less antigenic (data not shown) than the 9pp89 peptide that is bound naturally to the MHC
class I molecule Ld in infected cells (14). Notably, caspase-5 and caspase-10 generated
additional antigenic fractions (arrows), indicating a partial cleavage of m19 peptide to
generate smaller antigenic peptidic products. Control digestions in the presence of caspase-5
or caspase-10 inhibitors did not reveal any antigenic peaks other than the m19 substrate
(data not shown; see also later controls in Fig. 4B). Caspase-5 is a caspase-1–like initiator
proinflammatory caspase, whereas caspase-10 is an initiator caspase that triggers apoptosis.
Similar experiments were also performed with the proteasome. This multicatalytic complex
is also able to partially cleave the m19 peptide and produce smaller antigenic peptides (Fig.
3, last panel). The apparent yield of antigenically active products was lower after caspase-10
digestion, and specially after caspase-5 digestion, than after proteasome digestion (see
approximate quantitation after MS experiments below). In conclusion, the proteasome as
well as caspase-5 and caspase-10 are able to process m19 peptide independently and
generate products that are recognized by 9pp89-specific CTLs.
Identification by MS fragmentation of peptides generated by different proteases
Proteasomes are not dedicated to Ag processing and seldom produce the final antigenic
peptide. Rather, a collection of N-terminally extended precursors is frequently generated,
which, after further trimming by additional aminopeptidases, can give rise to the final
antigenic products. The same could apply to caspases. Fig. 3 revealed only antigenic
products. Therefore, our next aim was to further reveal potential relevant precursor peptides
generated by caspases. To this end, the peptides generated by the different proteases
involved in m19 processing were studied by micro-HPLC electrospray MS. Total digestions
with proteasome, caspase-5, or caspase-10 were analyzed extensively by MS/MS to detect
all relevant products (i.e., potential epitope precursors as well as the final epitope). Micro-
liquid chromatography coupled to MS/MS was used, and the analysis was restricted to each
theoretical parent ion and followed by manual interpretation (20). This technique was
employed because it increases peptide detection and optimizes the identification of
generated peptides, because it can resolve isomeric products generated from this
miniprotein. Fig. 4A summarizes the results. The proteasome generates mainly N-terminally
extended peptides with the correct C-terminal leucine residue, as reported previously (12,
20). Both caspase-5 and caspase-10 produced a broad spectrum of processed peptides. This
was unexpected given their canonical specificity. The nature and amount of these products
differed from those produced by proteasomes. Caspase-5 caused a major cleavage at a
canonical site after the three C-extended residues Ala-Gly-Asp, and caspase-10 induced a
major cleavage upstream of the exact N-terminal Tyr of 9pp89 epitope. Similar to the
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proteasome digestion, some peptides that can be relevant for Ag presentation were produced
by caspase-5, such as 1MDIGAYPHFMPTNL14, or by caspase-10, such
as 5AYPHFMPTNL14, and the exact optimally antigenic 6YPHFMPTNL14 9pp89
nonamer. The global yield of products generated by caspase-5 or caspase-10 was around
1/25 or 1/3 of the proteasome yield, respectively (data not shown). Peptide 1-17, having a
possible cleavage site on the carboxyl side of an aspartate residue, which would fit canonical
caspase activity, was found at low levels after electrospray ionization-MS in all cleavage
experiments, including the negative control experiments (m19 synthetic peptide with no
proteases and digestions in the presence of caspase inhibitors; Fig. 4B). Thus, no
conclusions could be drawn when low levels of this peptide were detected. This finding is in
agreement with a report that indicates that Asp-Pro bonds of synthetic peptides can undergo
spontaneous cleavage under acidic conditions, preferentially under those generally used in
solubilization and purification of peptides prior to electrospray ionization-MS analysis (26).
Of note, the lack of other peptidic products in these control digestions, as well as the
diversity of products generated by digestion with each enzyme, speaks for the purity of the
caspase preparations and supports their noncanonical specificities.
In summary, these results show that caspases can cleave at sites other than the specific
consensus sites reported previously, albeit with lower efficiency than the proteasome. Most
importantly, the products of these noncanonical cleavages include peptides that can be
recognized by CTLs, as well as potential N-extended precursor peptides for Ag presentation
in infected cells.
Proteasomes and caspases generate similar natural antigenic peptides in living infected
cells
Following the study of the products of in vitro processing by caspases, the natural
endogenously processed peptides derived from the m19 miniprotein and generated by both
independent pathways in infected cells were analyzed. To this end, we performed acid
extractions of the peptides generated after infection of L/Ld cells with rVACV-m19 in the
presence or absence of protease inhibitors. The peptides were separated by RP-HPLC and
their antigenicity was analyzed in cytotoxicity assays. Cells infected with m19 without
protease inhibitors showed one peak of antigenic activity (Fig. 5, empty circles). This
biological activity coelutes with the synthetic nonapeptide YPHFMPTNL, 9pp89, (data not
shown) reported previously as the natural CTL epitope in rVACV and murine CMV
infection (14, 27). The low levels of expression of unprocessed m19 did not allow detection
of its antigenicity in these whole-cell extracts (Fig. 5, arrow). 9pp89-specific CTLs did not
recognize control rVACV-infected target cells, indicating the specificity of the antigenic
peak (data not shown). Results in Fig. 2 had suggested that m19 can be processed in infected
cells either by proteasomes or caspases. Therefore, natural peptides were also extracted from
cells infected in the presence of proteasome inhibitor LC to reveal the products derived
mainly from the caspases pathway (Fig. 5, triangles) or from cells infected in the presence of
caspase inhibitor z-VAD-fmk to reveal the products derived mainly from the proteasomal
pathway (Fig. 5, squares). Both cell extracts showed similar antigenic activities, suggesting
that either pathway generates similar antigenic peptides in sufficient amount to allow
effective Ag presentation to CTLs.
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Activation of caspases in rVACV-m19–infected cells
Caspases are activated in different cells and also after vaccinia virus infection (7–9).
Therefore, caspase activation in L/Ld cells infected with rVACV-m19 was studied. As
shown in Fig. 6A, the same levels of activation were attained in cells infected with rVACV-
m19 as those observed following classical staurosporine-induced cell killing. This cellular
death was mediated by caspase activity because the presence of z-VAD-fmk specifically
impaired it (Fig. 6B).
Vaccinia virus wild-type strain WR expresses the B13 protein, which inhibits the
proinflammatory caspase-1, the IL-1–converting enzyme, in human (17) and murine cells
(28). B13 is closely related to crmA from cowpox virus. Like crmA, it blocks apoptosis (17,
28, 29) and thus is likely to also inhibit proapoptotic caspases. We reasoned that B13 might
target the z-VAD-fmk–sensitive enzymes involved in m19 presentation to CTLs. Analysis
with a WR strain of vaccinia virus lacking the B13R gene, vΔB13R, and with the revertant
control virus, vB13R+rev, shows, first, that induction of apoptosis by vΔB13R is infection-
and dose-dependent and, second, that apoptosis is inhibited by the B13 protein in L/Ld cells
infected with the revertant virus vB13R+rev (Fig. 6C). The B13R gene is naturally disrupted
in vaccinia virus strain Copenhagen, the parental virus for rVACV-m19 (Fig. 1). This
explains why rVACV-m19 infection induced apoptosis in Fig. 6A, 6B. To express the viral
apoptosis inhibitor B13 protein in cells expressing m19, cells were coinfected with rVACV-
m19 and with either one of the two WR-based vaccinia viruses. Fig. 6D shows that
apoptosis induced by rVACV-m19 decreased after coinfection with vB13R+rev but not with
control vΔB13R. Thus, in addition to inhibiting the proinflammatory caspase-1, vaccinia
virus B13 protein also prevented apoptosis in rVACV-m19–infected cells.
Blockade of the endogenous processing of 9pp89 epitope by LC combined with vaccinia
virus protein B13
Next, cytotoxic assays were performed with rVACV-m19–infected cells treated with the
proteasome inhibitor LC and coinfected with vaccinia viruses that do or do not encode the
gene B13R for the viral caspase inhibitor. These experiments were designed to mimic the
combined treatment with LC and the pan-caspase inhibitor z-VAD-fmk that blocks m19 Ag
presentation (Fig. 2). The results are shown in Fig. 7. When only the proteasome pathway
was blocked, by using LC only (Fig. 7A) or control vΔB13R and LC (Fig. 7B, left bar), Ag
presentation remained unaffected, as expected. In contrast, when both pathways were
blocked (by LC plus vaccinia virus expressing protein B13), Ag presentation was
considerably decreased (Fig. 7B, right bar). Therefore, because caspase inhibition by either a
chemical or a viral protein impairs recognition of infected cells by antiviral MHC class I-
restricted CTLs, these data substantiate that caspases are involved in m19 Ag processing.
Discussion
We have investigated the role of cytoplasmic nonproteasomal proteases in Ag presentation
of short viral Ags by MHC class I molecules in infected cells. By employing a chemical
inhibitor of caspases as well as a viral protein that inhibits caspases and apoptosis in infected
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cells, we find that caspases are involved in Ag presentation to CD8+ T lymphocytes of a
vaccinia virus-expressed viral epitope.
Each caspase has different substrate specificities determined by tetrapeptide motifs upstream
of the cleavage site, but all cleave mainly on the carboxyl side of an aspartate residue. Our
findings show that at least two human initiator caspases can process the m19 peptide in vitro
and that they generate a variety of peptidic products, some of which are recognized by
specific antiviral CD8+ T lymphocytes. The protease activity of these caspases was
unexpected in view of their reported cleavage specificity, and so these data establish an
additional minor new activity for these caspases. Extending recent results (30) in which a
model epitope was positioned at the end of a protein and had an engineered N-terminal
canonical cleavage site for caspase-3 and -7, we now show that, for efficient viral Ag
processing in infected cells, caspases do not need an optimal consensus cleavage site. This
ability broadens the repertoire of potential MHC ligands or precursors generated by
caspases. Precursor peptides are especially relevant for Ags like 9pp89 and for MHC class I
molecules like Ld and HLA-B7 supertype that preferentially bind peptides with a proline in
position 2, which is poorly transported by TAP (31). Furthermore, in addition to the
generation of potential precursor peptides, we show that caspases can generate with limited
efficiency both N and C ends of the viral peptide in vitro.
Our results also show that in vivo the 19-mer substrate peptide is processed naturally in
infected cells by caspases as well as by proteasomes. In our system, the production of a
similar final antigenic activity by either pathway in living cells may reflect the potential
ability of either protease to generate correct C-terminals aided by the likely contribution to
both pathways of downstream trimming by auxiliary enzymes (2, 3), followed by selection
by the MHC class I molecule Ld of the optimal binding peptide.
When processing of endogenously synthesized Ags proceeds independently of the classical
proteasome pathway, the involvement of three proteases of the secretory pathway, signal
peptidase (32, 33), furin (34–36), and cathepsins (36), has been reported. There are some
indications that cytosolic nonproteasomal endoproteases are involved in Ag processing (15,
37, 38), but their identification remains elusive. The exception is cytosolic tripeptidyl
peptidase II, which, in addition to acting as an aminopeptidase, exhibits an endoproteolytic
activity and contributes to the generation of at least some selected epitopes also when
proteasomes are inhibited (5, 6, 39). Caspases generate endoproteolytic cleavages, and the
current study shows that, as for tripeptidyl peptidase II, Ag processing of endogenous Ags
by these proteases can be detected when proteasomes are impaired. Caspases may thus also
be important under infection conditions under which proteasome activities cannot generate
given peptides or even directly destroy some epitopes (5, 6, 40). For this particular Ag, we
show that it can be processed by proteasomes and by at least two human caspases. There are
no exact murine counterpart genes for these caspases (41, 42). It is thus expected that in
murine cells, the viral Ag is processed by a set of zVAD-cmk- and B13-sensitive caspases
with canonical or noncanonical specificities related to those of human caspase-5 and -10.
We cannot anticipate whether this redundancy can be extended to other Ags. When the sole
effect of B13R deletion on selected epitopes was assayed in the absence of proteasome
blockade, no differences were found (43, 44). Our data thus demonstrate the existence of
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supplemental activities in the cytosolic Ag-processing pathway for presentation by MHC
class I molecules and identify the enzyme family involved.
A recent report showed that caspases can partially cleave cellular proteins in apoptotic cells,
suggesting that after endocytosis of apoptotic cells by dendritic cells, these partially cleaved
self-proteins would serve as substrates for the proteasome during cross-presentation to
autoreactive T lymphocytes (45). Our results show that caspases can fully process the viral
Ag already in the apoptotic infected cell, rendering it a target for elimination by antiviral
CD8+ T lymphocytes.
On the other hand, processing of Ags that are exogenously added to cells can also proceed
via a variety of proteases, including the proteasome and cathepsin S in professional APCs
and signal peptidase and furin in other cell types (46). Of note, these are the same proteases
as those involved in processing of endogenously synthesized viral proteins. We show in this
study that caspases in infected cells can process endogenous viral Ags. A relevant issue that
deserves further study is whether caspases in dendritic cells can also process endocytosed
Ags for cross-presentation, an event which contributes to initiating the antiviral CD8+ T
lymphocyte responses within hours of host infection (47).
Apoptosis by caspase activation is a universal cellular defense mechanism against viruses
and other intracellular pathogens, including vaccinia virus (7, 8), which interferes with virus
production and transmission to neighboring cells. As we show in this paper, as a spin-off
benefit, caspases process Ag. Therefore, these proteases are good candidates to increase the
diversity of the pool of viral peptides available for MHC binding, thereby complementing
the products of the proteasome and of the IFN-γ-induced immunoproteasomes. Like these
complexes, some caspases, including caspase-1 and caspase-5, are induced by IFN-γ
expressed during inflammation (48). It is plausible that the increase in caspase activation
that we observe postinfection may compensate for the lower efficiency of peptide
production in vitro by caspases as compared with the proteasome. In this context, it is
relevant that we study naturally induced apoptosis by vaccinia virus infection. Close to
physiological blockade of apoptosis and Ag presentation via caspases was also achieved
with the vaccinia virus protein B13 that was naturally expressed during infection. Our
results thus extend previous findings with an engineered model of induction of apoptosis
(30). Because caspases are selectively activated under infection or physiological stress, their
supplementary role in Ag processing may facilitate the production of MHC class I ligands
for Ag presentation in a critical moment postinfection. This regulation would decrease the
likelihood of immune escape by viruses or other pathogens. Not surprisingly, several
pathogens including vaccinia virus attenuate caspase activity by encoding inhibitors of
apoptosis and of caspases (7, 17). The inhibitory effects of the vaccinia virus apoptosis
inhibitor B13 both on apoptosis and Ag presentation are predicted to add up to favoring
virus replication in the infected host. Indeed, a virus deletion mutant lacking the B13R gene
is mildly attenuated after i.p. infection in vivo (49), although not if applied intranasally (50).
Apoptotic cells show endogenous adjuvant properties to initiate an immune response (51).
Our results support the notion that viral Ag presentation by caspases induced during
apoptosis also contributes to immunogenicity of apoptotic infected cells.
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FIGURE 1. Diagram showing nature of the rVACV.
The rVACV-m19 and all viruses derived from vaccinia virus strain Copenhagen have the
B13R gene disrupted. In contrast, this gene is functional in vaccinia virus strain WR.
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FIGURE 2. Ag-presentation assays with proteasome and caspases inhibitors.
L/Ld cells were infected overnight with 10 PFU/cell of rVACV-m19 or rVACV-m17 in the
presence of LC, z-VAD-fmk (z-VAD), or z-FA-fmk (z-FA) and tested with 9pp89-specific
CTLs (A, B). Similarly, L/Dd cells were infected with rVACV-sA (C) or rVACV-sI (D) and
tested with HIV ENV-specific CTLs. Inhibitors were present throughout infection and
during [51Cr] labeling until addition of specific CTLs to target cells. The percentage specific
lysis in the absence of LC was 45%, 50%, 45%, and 39% for m19, m17, sA, and sI,
respectively, and was used as a reference to calculate percentage of specific inhibition,
which is expressed as the mean ± SD (n = 6).
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FIGURE 3. In vitro digestions of m19 synthetic peptide with different caspases (Casp) or
proteasomes (Prot).
The m19 synthetic peptide was digested with the indicated purified proteases. Peptides
generated in each digestion were separated by RP-HPLC. Fractions were tested with 9pp89-
specific CTLs to analyze the presence of antigenic peptides. The results obtained with each
protease in the cytotoxicity assay are depicted. The arrows indicate antigenic peaks other
than the m19 substrate peptide.
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FIGURE 4. Digestion pattern of m19 synthetic peptide with purified proteasomes or different
caspases analyzed by MS.
The m19 synthetic peptide was digested with the indicated purified proteases (A) or negative
controls (B) and analyzed by MS/MS. The sequence of the CMV epitope is boxed.
Horizontal lines show peptide products identified by MS/MS analysis. Line thickness
indicates approximate amount detected. The arrows indicate cleavages. Their thickness
indicates frequency of each cleavage, deduced from the approximate amounts of identified
peptide products. Amounts are depicted relative to the most abundant product within each
digestion.
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FIGURE 5. Natural endogenous peptides generated after processing of m19 in infected cells.
Naturally processed peptides were acid-extracted from L/Ld cells infected overnight with 10
PFU/cell of rVACV-m19 in the presence of LC (■), z-VAD-fmk (▲), or nothing (○) and
separated by RP-HPLC. Fractions were tested with 9pp89-specific CTLs to analyze the
presence of antigenic peptides.
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FIGURE 6. Activation of caspases after vaccinia virus infection.
Inhibition by the vaccinia virus protein B13. L/Ld cells were infected for 4 h with the PFU/
cell shown in brackets with the indicated vaccinia viruses or combinations of two viruses
(A–D). Refer to Fig. 1 for presence of B13R in each virus. The percentage of apoptotic cells
was determined by flow cytometry after staining with CaspACE FITC-VAD-fmk. CTL-L2
cells in A were incubated for 4 h with 1 μM staurosporine (ST).
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FIGURE 7. Inhibition of Ag presentation to CTLs by a combination of LC and the vaccinia virus
protein B13.
L/Ld cells were singly infected overnight in the presence of LC with 10 PFU/cell of rVACV-
m19 (■) or a negative control (●) or doubly infected with 10 PFU/cell of either vΔB13R
(▲) or vB13R+rev (lines). LC was kept throughout infection and [51Cr] labeling until the
addition of CTLs to target cells. The percentage specific lysis at each E:T ratio is shown on
the vertical axis (A). The percentage specific inhibition caused by the coinfection is plotted
as the mean ± SD (n = 4) of all E:T ratios (B).
López et al. Page 21
J Immunol. Author manuscript; available in PMC 2014 October 20.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
